Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunctionWeier Qi, George L. King, Hillary A. Keenan et al.|Nature Medicine|2017Cited by 493
The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2Susanne Krasemann, Ole Pleß, Jessica Lisa Littau et al.|Stem Cell Reports|2022Cited by 239
A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disordersAimo Kannt, Saravanakumar Dhakshinamoorthy|Scientific Reports|2018Cited by 99
Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic NephropathyDaniel Gordin, George L. King, Hetal Shah et al.|Diabetes Care|2019Cited by 88
Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disordersSven Ruf, Aimo Kannt|Scientific Reports|2022Cited by 26